drugset / Trial / NCT03363945
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants
Phase 3
Completed
30 enrolled
Medeor Therapeutics, Inc.
California Institute for Regenerative Medicine (CIRM) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.
Timeline
- Start
- 2018-03-15
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SIZAVALEUCEL | Cell therapy | — | Intravenous |